Robin Forrest
@robinjforrest.bsky.social
Research Fellow (Harvard Pilgrim Health Care Institute / Harvard Med School) & PhD Candidate (The London School of Economics)
Reposted by Robin Forrest
Relevant to accelerated approval, new DCE from former @portalresearch.org fellow Huseyin Naci et al examined patient views on survival benefit for cancer drugs: "individuals expressed strong preferences for certainty that a cancer drug would offer survival benefit" www.thelancet.com/journals/lan...
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment
Many cancer drugs approved through the FDA's accelerated approval pathway do not offer
any survival benefit to patients. In this study, individuals expressed strong preferences
for certainty that a ca...
www.thelancet.com
November 23, 2024 at 1:19 PM
Relevant to accelerated approval, new DCE from former @portalresearch.org fellow Huseyin Naci et al examined patient views on survival benefit for cancer drugs: "individuals expressed strong preferences for certainty that a cancer drug would offer survival benefit" www.thelancet.com/journals/lan...